JP2024507221A - Ｒａｆ阻害剤とｍｅｋ阻害剤の組合せ - Google Patents

Ｒａｆ阻害剤とｍｅｋ阻害剤の組合せ Download PDF

Info

Publication number
JP2024507221A
JP2024507221A JP2023550043A JP2023550043A JP2024507221A JP 2024507221 A JP2024507221 A JP 2024507221A JP 2023550043 A JP2023550043 A JP 2023550043A JP 2023550043 A JP2023550043 A JP 2023550043A JP 2024507221 A JP2024507221 A JP 2024507221A
Authority
JP
Japan
Prior art keywords
braf
subject
cancer
administered
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023550043A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024507221A5 (https=
JPWO2022178244A5 (https=
Inventor
サミュエル シー． ブラックマン，
エレニ ベネトサナコス，
Original Assignee
デイ ワン バイオファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デイ ワン バイオファーマシューティカルズ， インコーポレイテッド filed Critical デイ ワン バイオファーマシューティカルズ， インコーポレイテッド
Publication of JP2024507221A publication Critical patent/JP2024507221A/ja
Publication of JP2024507221A5 publication Critical patent/JP2024507221A5/ja
Publication of JPWO2022178244A5 publication Critical patent/JPWO2022178244A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023550043A 2021-02-19 2022-02-18 Ｒａｆ阻害剤とｍｅｋ阻害剤の組合せ Pending JP2024507221A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163151425P 2021-02-19 2021-02-19
US63/151,425 2021-02-19
US202163173158P 2021-04-09 2021-04-09
US63/173,158 2021-04-09
PCT/US2022/016962 WO2022178244A1 (en) 2021-02-19 2022-02-18 Combination of raf inhibitor and mek inhibitor

Publications (3)

Publication Number Publication Date
JP2024507221A true JP2024507221A (ja) 2024-02-16
JP2024507221A5 JP2024507221A5 (https=) 2025-02-27
JPWO2022178244A5 JPWO2022178244A5 (https=) 2025-02-27

Family

ID=82931723

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023550043A Pending JP2024507221A (ja) 2021-02-19 2022-02-18 Ｒａｆ阻害剤とｍｅｋ阻害剤の組合せ

Country Status (10)

Country Link
US (1) US20240058338A1 (https=)
EP (1) EP4294400A4 (https=)
JP (1) JP2024507221A (https=)
KR (1) KR20230147136A (https=)
AU (1) AU2022223437A1 (https=)
CA (1) CA3211167A1 (https=)
IL (1) IL305250A (https=)
MX (1) MX2023009642A (https=)
WO (1) WO2022178244A1 (https=)
ZA (1) ZA202307921B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4408430A4 (en) * 2021-10-01 2025-07-30 Day One Biopharmaceuticals Inc RAF KINASE INHIBITORS FOR THE TREATMENT OF TUMORS WITH GENE FUSIONS
WO2025106686A1 (en) * 2023-11-15 2025-05-22 Day One Biopharmaceuticals, Inc. Methods of treating pediatric low-grade glioma

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015511632A (ja) * 2012-03-30 2015-04-20 武田薬品工業株式会社 メラノーマの治療におけるｒａｆ阻害剤およびｍｅｋ阻害剤の投与
JP2020532982A (ja) * 2017-09-08 2020-11-19 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト がんの診断及び治療方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3240745A1 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatment using combinations of erk and raf inhibitors
UY36046A (es) * 2014-03-26 2015-10-30 Millennium Pharm Inc Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
WO2016025648A1 (en) * 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinations of an erk inhibitor and a raf inhibitor and related methods

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015511632A (ja) * 2012-03-30 2015-04-20 武田薬品工業株式会社 メラノーマの治療におけるｒａｆ阻害剤およびｍｅｋ阻害剤の投与
JP2020532982A (ja) * 2017-09-08 2020-11-19 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト がんの診断及び治療方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DAY ONE (BIOPHARMACEUTICALS), [ONLINE], JPN6026001392, 22 November 2021 (2021-11-22), pages 2026 - 1, ISSN: 0005772844 *
MOLECULAR CANCER THERAPEUTICS, vol. 14, no. 12, JPN6026001389, 2015, pages 2700 - 2711, ISSN: 0005772842 *
RECORD HISTORY: NCT04985604, DAY ONE ANNOUNCES FIRST PATIENT DOSED IN PHASE 2 MONOTHERAPY STUDY IN R, JPN6026001391, 25 January 2022 (2022-01-25), ISSN: 0005772845 *
TARGETED ONCOLOGY, 2021, vol. 16, no. 1, JPN6026001390, 19 November 2020 (2020-11-19), pages 47 - 57, ISSN: 0005772843 *

Also Published As

Publication number Publication date
ZA202307921B (en) 2024-04-24
EP4294400A1 (en) 2023-12-27
WO2022178244A1 (en) 2022-08-25
MX2023009642A (es) 2023-10-16
EP4294400A4 (en) 2025-01-01
US20240058338A1 (en) 2024-02-22
AU2022223437A1 (en) 2023-09-07
IL305250A (en) 2023-10-01
CA3211167A1 (en) 2022-08-25
KR20230147136A (ko) 2023-10-20

Similar Documents

Publication Publication Date Title
KR102258698B1 (ko) B-Raf 억제제와 제2 억제제를 포함하는 조합 요법
JP7058345B2 (ja) Ｂｃｌ－２阻害剤及びＭＤＭ２阻害剤の組合せ製品並びに疾患の予防及び／又治療におけるその使用
CN107949387B (zh) 用谷氨酰胺酶抑制剂治疗肺癌
CA3180314A1 (en) Methods of treating cancer in patients with an anomalous kras gene or deletions within chromosome 9
JP2022508183A (ja) 神経芽細胞腫の治療における使用のためのオーロラａキナーゼ阻害剤
JP2023145689A (ja) Ｈｅｒ２陽性がんの処置
JP2005508856A (ja) 血管形成を阻害する方法
JP2021534129A (ja) Ｅｇｆｒ変異がんの処置
US20240058338A1 (en) Combination of raf inhibitor and mek inhibitor
TW202221118A (zh) 複製壓力路徑劑組合物及治療癌症之方法
JP2024012649A (ja) Ｃｈｋ１阻害剤を含む癌の治療方法
JP7570641B2 (ja) 癌の処置又は予防において使用する為のキノリン誘導体
BR112021007237A2 (pt) métodos para o tratamento de uma vasculopatia em um indivíduo e para o tratamento de um transtorno do tecido conjuntivo em um indivíduo, kit, e, composição farmacêutica para o tratamento de uma vasculopatia
JP6908287B2 (ja) 脳腫瘍の処置のための治療剤としての２−アミノピリミジン誘導体
WO2022161364A1 (zh) 通路调节剂、含其的药物组合物、其用途和采用其的治疗方法
WO2025157287A1 (zh) 包含prmt5抑制剂和egfr抑制剂的药物组合物
EA015933B1 (ru) Лечение детских опухолей
JP6267619B2 (ja) 慢性骨髄性白血病の治療用組成物
EP4051273A1 (en) Treatment of renal cystic disease
CN117177754A (zh) Raf抑制剂和mek抑制剂的组合
RU2811417C2 (ru) Производные хинолина для применения в лечении или предупреждении рака
TW202506115A (zh) 一種藥物組合及其應用
WO2022271939A1 (en) Erk1/2 and cdk4/6 inhibitors combination therapy
HK40118235A (zh) 用於治疗或预防癌症的喹啉衍生物
TW202521118A (zh) 治療alk陽性或ros1陽性的非小細胞肺癌的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260116

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260121